Drug intelligence / Profile preview

pertuzumab + trastuzumab + capecitabine

Development stage: Unknown
Lead developer: Roche
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

This is a combination therapy consisting of two monoclonal antibodies (pertuzumab and trastuzumab) that target different domains of the HER2 receptor, along with capecitabine, an oral chemotherapy agent. Pertuzumab prevents the formation of HER2:HER3 dimers, while trastuzumab binds to a different domain of HER2. Capecitabine is a prodrug that is converted to 5-fluorouracil in the body, interfering with DNA synthesis. This combination is primarily used for HER2-positive breast cancer that has progressed during or following trastuzumab-based therapy.

Targets

TS (Thymidylate synthase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on pertuzumab + trastuzumab + capecitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pertuzumab + trastuzumab + capecitabine.

Explore the full profile